Related Experiment Video
Updated: Mar 7, 2026
09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
19.1K
Tolcapone Interferes With Key Pathological Features in Alzheimer's Disease
Alessia Distefano1, Damiano Calcagno2, Giuseppe Grasso1
1Università degli Studi di Catania, v.le A. Doria 6, Catania, 95125, Italy, unict.it.
Bioinorganic Chemistry and Applications
|March 6, 2026
Summary
Tolcapone, a Parkinson's disease drug, shows potential for Alzheimer's disease by binding to amyloid-beta and preventing toxic metal interactions. This suggests new therapeutic avenues for neurodegenerative disorders.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Amyloid-beta (Aβ) aggregation and toxicity are key features of Alzheimer's disease (AD) and other neurodegenerative conditions.
- Tolcapone, a drug for Parkinson's disease, has shown potential in modulating Aβ aggregation, but its molecular interactions are not well understood.
Purpose of the Study:
- To investigate the binding interactions between tolcapone and both copper-free and copper-associated amyloid-beta species.
- To explore the mechanisms by which tolcapone affects metal-amyloid-beta complexes.
Main Methods:
- UV-vis spectroscopy
- Circular dichroism
- Mass spectrometry
- Surface plasmon resonance
- In vitro radical scavenging assays
Main Results:
- Tolcapone directly binds to amyloid-beta monomers.
- Tolcapone acts as a radical scavenger.
- Tolcapone competes with amyloid-beta for copper ion binding.
- Tolcapone can prevent metal coordination to Aβ and disrupt preformed Aβ-metal complexes.
Conclusions:
- Tolcapone exhibits multifaceted protective effects against amyloid-beta aggregation and toxicity.
- The drug's ability to interfere with metal-amyloid-beta interactions offers new therapeutic strategies for neurodegenerative diseases.
- Tolcapone analogs may be developed for treating conditions like Alzheimer's disease and glaucoma.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
01:26Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
01:29Drugs Affecting Neurotransmitter Synthesis
2.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.4K
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.7K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.7K
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
319
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
319